Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
about
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.
P2860
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@ast
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@en
type
label
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@ast
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@en
prefLabel
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@ast
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@en
P2093
P2860
P50
P1433
P1476
Impact of IL28B, APOH and ITPA ...... from the ANRS CO20-CUPIC Study
@en
P2093
ANRS CO20-CUPIC study group
Carole Cagnot
Christophe Hézode
Darragh Duffy
Dominique Larrey
Fabien Zoulim
Hélène Fontaine
Ioannis Theodorou
Jean-Pierre Bronowicki
Jonathan Niay
P2860
P304
P356
10.1371/JOURNAL.PONE.0145105
P407
P577
2015-12-15T00:00:00Z